Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate

被引：0
|
作者：
Akira Sawaki
Yasuhide Yamada
Yoshito Komatsu
Tatsuo Kanda
Toshihiko Doi
Masato Koseki
Hideo Baba
Yu-Nien Sun
Koji Murakami
Toshirou Nishida
机构：
[1] Aichi Cancer Center Hospital,Department of Gastroenterology
[2] National Cancer Center Hospital,Gastrointestinal Oncology Division
[3] Hokkaido University Hospital,Department of Gastroenterology
[4] Niigata University Hospital,Digestive and General Surgery 2 Division
[5] National Cancer Center Hospital East,Division of Gastrointestinal Oncology
[6] National Hospital Organization Kure Medical Center,Department of Surgery
[7] Kumamoto University Hospital,Department of Surgical Pathology
[8] Amgen Inc.,Department of Pharmacokinetics and Drug Metabolism
[9] Dokkyo University School of Medicine,PET Center
[10] Osaka University Hospital,Department of Digestive Surgery
来源：
Cancer Chemotherapy and Pharmacology | 2010年 / 65卷
关键词：
Motesanib; Angiogenesis inhibitor; Gastrointestinal stromal tumor (GIST);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：961 / 967
页数：6
相关论文
共 50 条
  • [31] Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
    Sumin Tang
    Yuan Yin
    Chaoyong Shen
    Jiaju Chen
    Xiaonan Yin
    Bo Zhang
    Yuqin Yao
    Jinliang Yang
    Zhixin Chen
    World Journal of Surgical Oncology, 15
  • [32] MDCT appearance of gastrointestinal stromal tumors after therapy with imatinib mesylate
    Warakaulle, DR
    Gleeson, F
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2006, 186 (02) : 510 - 515
  • [33] CT evaluation of gastrointestinal stromal tumors treated with imatinib mesylate - Reply
    Choi, H
    Johnson, MM
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2005, 185 (05) : 1366 - 1367
  • [34] One institutional experience with imatinib mesylate in the treatment of gastrointestinal stromal tumors
    Tamas, Karin R.
    Papai, Zsuzsa
    Vegh, Eva A.
    Petranyi, Agota E.
    Szucs, Zoltan
    Rohanszky, Magda
    Aranyi, Zsuzsa
    Bodoky, Gyorgy
    ANNALS OF ONCOLOGY, 2006, 17 : 164 - 164
  • [35] Clinical response to imatinib mesylate in recurrent and metastatic gastrointestinal stromal tumors
    Villalobos, R.
    Hernandez, G.
    Martinez-Prieto, M.
    Silva, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [36] Early results from randomized phase III trial of imatinib mesylate for gastrointestinal stromal tumors
    Shreyaskumar R. Patel
    Current Oncology Reports, 2003, 5 (4) : 304 - 304
  • [37] Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
    Tang, Sumin
    Yin, Yuan
    Shen, Chaoyong
    Chen, Jiaju
    Yin, Xiaonan
    Zhang, Bo
    Yao, Yuqin
    Yang, Jinliang
    Chen, Zhixin
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2017, 15
  • [38] Cost Effectiveness of Imatinib Mesylate in the Treatment of Advanced Gastrointestinal Stromal Tumours
    Daniel M. Huse
    Margaret von Mehren
    Gregory Lenhart
    Heikki Joensuu
    Charles Blanke
    Weiwei Feng
    Stan Finkelstein
    George Demetri
    Clinical Drug Investigation, 2007, 27 : 85 - 93
  • [39] Sunitinib in Japanese patients with GIST after prior treatment with imatinib mesylate: A phase I/II dose-escalation study
    Doi, V
    Shirao, K.
    Yamada, Y.
    Muro, K.
    Fuse, N.
    Euda, E.
    Li, Y.
    Togo, K.
    Baum, C.
    Ohtsu, A.
    ANNALS OF ONCOLOGY, 2006, 17 : 101 - 101
  • [40] Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours
    Huse, Daniel M.
    von Mehren, Margaret
    Lenhart, Gregory
    Joensuu, Heikki
    Blanke, Charles
    Feng, Weiwei
    Finkelstein, Stan
    Demetri, George
    CLINICAL DRUG INVESTIGATION, 2007, 27 (02) : 85 - 93
12345